A patient on sertraline 75 mg daily for 4 weeks has persistent OCD ruminations/compulsions and anxiety; how should the treatment be adjusted?

Increase sertraline to at least 150-200 mg daily and continue for a full 8-12 weeks before considering the trial adequate

At 4 weeks on 75 mg daily, this patient has not received an adequate trial of sertraline for OCD—both the dose and duration are insufficient. The current dose is below the therapeutic range for OCD, and guidelines clearly indicate that 8-12 weeks at maximum recommended or tolerated doses is required to determine efficacy 1.

Immediate Management Steps

Dose Optimization

• Increase sertraline to 150-200 mg daily (the FDA-approved range for OCD is 50-200 mg/day) 2
• OCD requires higher SSRI doses than depression or other anxiety disorders—this is a critical distinction 1
• Titrate gradually (dose changes should not occur at intervals less than 1 week given sertraline's 24-hour half-life) 2
• The mean effective dose in clinical trials was approximately 150-200 mg/day 3, 4

Duration of Trial

• Continue at maximum tolerated dose for at least 8-12 weeks before declaring treatment failure 1
• While some improvement may be seen by 2-4 weeks, the greatest incremental gains occur early but full response requires the full trial duration 1
• Recent evidence suggests that lack of improvement at 4 weeks predicts nonresponse in 86% of cases, but this applies to patients already on adequate doses 5—this patient is not yet on an adequate dose

Important Caveats

Common pitfall: Declaring SSRI failure prematurely before reaching adequate dose and duration. Many patients labeled as "treatment-resistant" have simply not received an optimized trial 1.

Monitor for:

• Adverse effects (gastrointestinal symptoms, sexual dysfunction) which increase with higher doses but are manageable 1
• Serotonin syndrome if combining with other serotonergic agents 2
• Tolerability—adjust to the highest dose the patient can tolerate, not necessarily the maximum 1

If Inadequate Response After Optimized Trial

Only after 8-12 weeks at 150-200 mg daily should you consider:

1. Add CBT with exposure and response prevention (ERP)—this has the largest effect size for augmentation, superior to antipsychotic augmentation 1

2. Switch to a different SSRI or clomipramine 1

3. Increase beyond 200 mg/day (off-label): Evidence supports doses of 250-400 mg/day in nonresponders, showing significantly greater symptom improvement than 200 mg/day 3

4. Augmentation strategies (only after adequate SSRI trial):

   • Antipsychotics (risperidone, aripiprazole) 1
   • Clomipramine added to SSRI (requires careful monitoring for drug interactions and serotonin syndrome) 1
   • Glutamatergic agents (N-acetylcysteine, memantine) 1

Key Algorithmic Decision Points

Is the patient on an adequate dose?

• No → Increase to 150-200 mg daily

Has the patient been on adequate dose for 8-12 weeks?

• No → Continue current dose and reassess at 8-12 weeks
• Yes, with inadequate response → Consider augmentation or switching

Is CBT available?

• Yes → Add CBT (preferred augmentation strategy)
• No → Consider pharmacological augmentation or switch

The evidence strongly supports that this patient needs dose optimization first before any consideration of treatment resistance or augmentation strategies 1, 2.